Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Non-Current Assets (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Non-Current Assets data on record, last reported at $8.1 million in Q1 2026.

  • On a quarterly basis, Non-Current Assets fell 19.74% to $8.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $35.4 million, a 23.74% decrease, with the full-year FY2025 number at $8.8 million, down 18.44% from a year prior.
  • Non-Current Assets reached $8.1 million in Q1 2026 per FULC's latest filing, down from $8.8 million in the prior quarter.
  • Over the last five years, Non-Current Assets for FULC hit a ceiling of $21.0 million in Q2 2022 and a floor of $8.1 million in Q1 2026.
  • A 5-year average of $14.4 million and a median of $14.6 million in 2024 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: surged 124.02% in 2022, then plummeted 32.25% in 2025.
  • Tracing FULC's Non-Current Assets over 5 years: stood at $19.2 million in 2022, then dropped by 19.15% to $15.5 million in 2023, then crashed by 30.33% to $10.8 million in 2024, then dropped by 18.44% to $8.8 million in 2025, then decreased by 7.99% to $8.1 million in 2026.
  • Business Quant data shows Non-Current Assets for FULC at $8.1 million in Q1 2026, $8.8 million in Q4 2025, and $9.0 million in Q3 2025.